A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects
Study sponsor: Enanta Pharmaceuticals, Inc · ENTA
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-01-04Actual
Enrollment · participants82Actual
Source updated2023-10-30Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.